Serious Adverse Events Associated with Tocilizumab in COVID-19 Patients
Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.
Telehealth Diet and Exercise Benefits Knee Osteoarthritis
Annals of Internal Medicine has reported the results of a randomized clinical trial showing that telehealth-delivered exercise and diet programs improved pain and function in knee osteoarthritis patients who were overweight. While both were beneficial, exercise had a greater effect than die
Telemedicine Upside Interview with Dr. Alvin Wells
In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologys use of telemedicine is waning, much like the masks that use to be on everyones face.
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE
It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus?
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE
Lupus is a disease that disproportionately affects minorities and patients of color. In the past worse disease activity, severity as well as outcomes have been described in African American and Hispanic patients.
RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Abstract Numbers below:
Psoriatic arthritis
Can "Ultra-low" dose Rituximab work for RA?
At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art
Day 4 Report from ACR21
My favorite three presentations from day 4 at ACR 2021 included the following:
Breakthrough Infections in Rheumatic Disease Patients
ACR21 – Day 3 Report
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:
Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Social
Even young SLE patients are still at high risk of severe COVID:
- in general pop, age is key factor
- in SLE, risk is high across age groups (maybe due to both meds & disease)
- vaccination makes a big diff but SLE pts still at high risk
ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
David Liew @drdavidliew ( View Tweet )
2 years 5 months ago
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group
@RheumNow https://t.co/iucDK1GpU4
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
The pandemic has brought many challenges to our community. One of them is the lingering effects of COVID-19.
#PASC #COVID #ACR22 #RheumTwitter
https://t.co/AlwUHX2cao
Akhil Sood MD @AkhilSoodMD ( View Tweet )
2 years 5 months ago
All monster stories end with an unexpected award: A new order
@cuttingforstone at #ACR22 tells the monster story of #covid
“How will history review our story?”
The science will get an A+, but we failed to learn the lessons of history
All was predictable through history
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
2 years 5 months ago
Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu
Janet Pope @Janetbirdope ( View Tweet )
2 years 5 months ago
Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts?
Single-center (n=126) with one MTX dose WH post-each vaccine
Similar humoral response
Big error bars suggest other factors more important
ABST0913 #ACR22 @RheumNow
(not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY
David Liew @drdavidliew ( View Tweet )
2 years 5 months ago
💉COVID-19 vaccination in pregnant pts with rheumatic disease💉
🤰⬇️pre term births in vaccinated
🤰PPROM ⬆️ unvaccinated
✅More support 4 importance of covid vacc in our 🤰
Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W
Patricia Harkins @DrTrishHarkins ( View Tweet )
2 years 5 months ago
#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 5 months ago
Ab0685 #ACR22 APLS and prior COVID infection
TKR patients at HSS:
1/5 of patients had positive aPL Ab, mostly low level aCL IgM
Not associated with COVID infection or SARS-CoV-2 Ab
@RheumNow https://t.co/HJpnUOrrxc
Eric Dein @ericdeinmd ( View Tweet )
2 years 5 months ago
